Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

340.40INR
10:22am GMT
Change (% chg)

Rs-9.00 (-2.58%)
Prev Close
Rs349.40
Open
Rs344.00
Day's High
Rs349.80
Day's Low
Rs339.20
Volume
862,965
Avg. Vol
2,148,966
52-wk High
Rs456.75
52-wk Low
Rs332.25

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says Zydus Gets USFDA Nod For Lansoprazole, Linagliptin Tablets
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES APPROVALS FROM USFDA FOR LANSOPRAZOLE TABLETS AND LINAGLIPTIN TABLETS.ZYDUS GETS FINAL USFDA APPROVAL FOR LANSOPRAZOLE TABLETS AND TENTATIVE APPROVAL FOR LINAGLIPTIN TABLETS.LANSOPRAZOLE WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.LINAGLIPTIN WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval From USFDA For Baclofen Tablets
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM THE USFDA FOR BACLOFEN TABLETS.BACLOFEN TABLETS IS USED TO TREAT MUSCLE SPASMS CAUSED BY CONDITIONS SUCH AS MULTIPLE SCLEROSIS, SPINAL CORD INJURY/DISEASE.BACLOFEN TABLETS WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT BADDI.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Two Drugs
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES APPROVALS FROM USFDA FOR ATORVASTATIN CALCIUM TABLETS AND DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES.ATORVASTATIN DRUG TO BE MANUFACTURED AT FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.ATORVASTATIN IS USED TO HELP LOWER BAD CHOLESTEROL AND FATS AND RAISE GOOD CHOLESTEROL IN THE BLOOD.DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES WILL BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.DIMETHYL FUMARATE DRUG INDICATED FOR TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.  Full Article

Cadila Healthcare Says Zydus Gets Tentative Approval From USFDA For Deferasirox Tablets
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DEFERASIROX TABLETS.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Final Approval For Abacavir & Lamivudine Tablets
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE - ZYDUS GETS FINAL APPROVAL FROM THE USFDA FOR ABACAVIR & LAMIVUDINE TABLETS AND FONDAPARINUX SODIUM INJECTION.WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Updates On News Item On Drug Of Substandard Quality
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Cadila Healthcare Ltd ::CLARIFIES ON NEWS ITEM ON DRUG OF SUBSTANDARD QUALITY.GOT LETTER ON 22 JUNE FROM ASSISTANT DRUG CONTROLLER, KOCHI DECLARING ZIPCET TABLETS BATCH WAS NOT OF A STANDARD QUALITY.HAD RECALLED BATCH FROM MARKET ON JUNE 29.  Full Article

Zydus Wellness Says Deal To Buy Heinz India Expected To Be EPS Accretive
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Zydus Wellness Ltd ::DEAL TO BUY HEINZ INDIA IS EXPECTED TO BE EPS ACCRETIVE.DEAL ALSO INCLUDE 2 LARGE MANUFACTURING FACILITIES IN ALIGARH, SITARGANJ, TEAMS FOR OPERATIONS, RESEARCH, SALES,MARKETING AND SUPPORT.  Full Article

Zydus Wellness, Cadila Healthcare To Jointly Acquire Heinz India For 45.95 Bln Rupees
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Zydus Wellness Ltd ::SAYS PROPOSES TO ACQUIRE 100 PCT OF EQUITY SHARE CAPITAL OF HEINZ INDIA PRIVATE LIMITED.COST OF ACQUISITION IS 45.95 BILLION RUPEES.SAYS CONSIDERATION WILL BE IN CASH WHICH WILL BE FUNDED THROUGH A COMBINATION OF DEBT AND EQUITY.SAYS COMPANY HAS SIGNED THE SHARE PURCHASE AGREEMENT JOINTLY WITH CADILA HEALTHCARE LIMITED FOR THE DEAL.SAYS DEAL TO INCLUDE RIGHTS FOR GLUCON-D, NYCIL, SAMPRITI GHEE AND COMPLAN.  Full Article

Kraft Agrees To Sell Portfolio Of Indian Businesses To Zydus - Bloomberg
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - :KRAFT AGREES TO SELL PORTFOLIO OF INDIAN BUSINESSES TO ZYDUS - BLOOMBERG, CITING SOURCES.  Full Article

Cadila Healthcare Gets Zero 483 Observations For Ahmedabad Plant
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - Cadila Healthcare Ltd ::SAYS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA.SAYS AHMEDABAD PLANT HAD COMPLETED USFDA AUDIT FROM 14TH AUGUST TO 24TH AUGUST 2018 WITH ZERO 483 OBSERVATIONS.  Full Article

Kraft Heinz to sell part of India business for about $630 million

Kraft Heinz Co will sell part of its Indian business, including brands such as malt-based drink Complan and energy drink Glucon-D, for 45.95 billion rupees ($627.18 million), at a time when Indian consumers are demanding healthier, sugar-free alternatives.